Orexin-A vs C-peptide
Head-to-head comparison of Orexin-A (Hypocretin-1 (Orexin-A)) and C-peptide (Connecting peptide (C-peptide)) — benefits, dosing, side effects, research data, and where to buy.
| Property | Orexin-A | C-peptide |
|---|---|---|
| Category | Cognitive Enhancement | Pain Management |
| Full Name | Hypocretin-1 (Orexin-A) | Connecting peptide (C-peptide) |
| Molecular Weight | 3562 Da | 3020.3 Da |
| Half-Life | Minutes to <1 hour | ~20-30 min |
| Amino Acids | 33 | 31 |
| Typical Dose | Research-only; no validated human dose | no approved analgesic dose|research-only |
| Route | Intracerebroventricular/Intranasal | IV|subQ |
| Purity | ≥98% | ≥98% |
| Studies Count | 42 | 46 |
| Research Status | Pre-clinical | Pre-clinical |
Orexin-A Benefits
- ✓wakefulness
- ✓attention
- ✓memory consolidation
- ✓fatigue resistance
C-peptide Benefits
- ✓diabetic neuropathy research
- ✓nerve function support
- ✓possible analgesic effect
Orexin-A Dosing
Research-only i.c.v. microgram/nanomolar studies|intranasal experimental use|no established human protocol
C-peptide Dosing
0.5-1.0 mg/day in research|route varies by protocol
Orexin-A Side Effects
- ⚠insomnia
- ⚠headache
- ⚠blood pressure changes
C-peptide Side Effects
- ⚠injection-site reactions
- ⚠unknown long-term safety
Research Overview
Orexin-A
Preclinical studies link orexin signaling to arousal, learning, and memory consolidation, making orexin-A a candidate for cognition-related research. It is not an approved cognitive enhancer and remains an experimental peptide.
C-peptide
C-peptide is not an approved analgesic, but multiple studies have examined its effects on peripheral nerve blood flow and neuropathy outcomes. The strongest relevance is in diabetic neuropathic pain rather than migraine.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.